Hansa Biopharma's Idefirix achieves 90% graft failure-free survival at 12 months, with patient survival rates hitting 98%, signaling strong clinical validation for the treatment.
Hansa Biopharma's Idefirix has demonstrated strong clinical performance with a 90% graft failure-free survival rate at the 12-month mark. These positive post-authorization efficacy study (PAES) results validate the drug's therapeutic value and safety profile, which are critical for its ongoing commercial adoption in transplant medicine.
The 1-year graft failure-free survival rate at 12 months post-transplant was 90%.
Idefirix was reported to be generally well tolerated, with a safety profile consistent with previous clinical trial experience.
Hansa Biopharma announced positive 12-month data from its Idefirix PAES study, demonstrating a 90% graft failure-free survival rate. These clinical results reinforce the drug's efficacy and safety profile, potentially strengthening the company's commercial position in the transplant market.
The study reported a 90% graft failure-free survival rate and a 98% patient survival rate at 12 months post-transplant.